Travere Therapeutics Inc
NASDAQ:TVTX

Watchlist Manager
Travere Therapeutics Inc Logo
Travere Therapeutics Inc
NASDAQ:TVTX
Watchlist
Price: 18.93 USD 4.13% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Travere Therapeutics Inc?
Write Note

Travere Therapeutics Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Travere Therapeutics Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Travere Therapeutics Inc
NASDAQ:TVTX
Gross Profit
$193.7m
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
30%
Abbvie Inc
NYSE:ABBV
Gross Profit
$37.3B
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
9%
Gilead Sciences Inc
NASDAQ:GILD
Gross Profit
$22B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Gross Profit
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Gross Profit
$9.2B
CAGR 3-Years
13%
CAGR 5-Years
24%
CAGR 10-Years
29%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Gross Profit
$12B
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
17%
No Stocks Found

Travere Therapeutics Inc
Glance View

Market Cap
1.5B USD
Industry
Biotechnology

Travere Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 310 full-time employees. The company went IPO on 2003-07-23. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its products include Chenodal (chenodiol tablets), Cholbam (cholic acid capsules), and Thiola and Thiola EC (tiopronin tablets). Chenodal, which is for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Cholbam, which is for the treatment of bile acid synthesis disorders due to single enzyme defects. Thiola and Thiola EC, which are for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The firm's clinical program Sparsentan (RE-021), is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (ERA), with in vitro selectivity toward endothelin receptor type A, and a potent angiotensin receptor blocker.

TVTX Intrinsic Value
21.94 USD
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Travere Therapeutics Inc's Gross Profit?
Gross Profit
193.7m USD

Based on the financial report for Sep 30, 2024, Travere Therapeutics Inc's Gross Profit amounts to 193.7m USD.

What is Travere Therapeutics Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
30%

Over the last year, the Gross Profit growth was 31%. The average annual Gross Profit growth rates for Travere Therapeutics Inc have been -3% over the past three years , 3% over the past five years , and 30% over the past ten years .

Back to Top